Acquisition would enhance Accenture’s
comprehensive services to public- and private-sector companies
across the health, life sciences and insurance industries
Accenture (NYSE: ACN) has entered into an agreement to acquire
Paris-based OpusLine, one of the leading consulting companies that
provides strategic advisory and transformational services to
public- and private-sector healthcare providers as well as life
sciences and insurance companies in France.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20201027005133/en/
Accenture to acquire OpusLine (Graphic:
Business Wire)
Following the acquisition of OpusLine, Accenture would be better
positioned to provide health industry clients with the latest
innovations in areas such as data analytics and artificial
intelligence (AI) and support the health ecosystem with highly
differentiated services.
“Our intent to acquire OpusLine is aligned with our development
strategy and underscores our commitment to the health industry,
which is a fast-growing sector for Accenture and also for society
as a whole,” said Olivier Girard, market unit lead for Accenture
France & Benelux. “OpusLine’s extensive industry knowledge
complements Accenture’s deep technology expertise and would provide
our clients in France with even greater access to local and global
industry expertise as they embrace new technologies and
processes.”
Founded in 2012, OpusLine is one of France’s largest independent
health consulting companies, employing more than 85 consultants.
Following the acquisition, OpusLine’s employees would join the
newly created Health practice of Accenture Strategy &
Consulting and enhance its ability to help clients innovate and
deliver digital innovation across their organizations.
“The opportunity to become part of Accenture presents tremendous
new opportunities for our business, our clients and our people,”
said Alix Pradere, OpusLine’s founder and associate partner. “We
are particularly excited about the opportunity to leverage
Accenture’s capabilities in digital and cybersecurity to deliver
enhanced patient and customer experiences and to also ensure we
remain at the forefront of industry innovation.”
Aliette Leleux, managing director of Accenture’s insurance
industry practice in France, said: “The transformation and the
digitalization of the healthcare and insurance industries are a
priority for stakeholders across the public and private sectors.
OpusLine’s talented team of professionals would support our
objective of providing clients with efficient and innovative
solutions that integrate the latest technologies such as robotics,
artificial intelligence, the internet of things and
cybersecurity.”
This transaction follows other healthcare- and life
sciences-related acquisitions by Accenture in recent years,
including the 2019 acquisitions of Clarity Insights, Knowledgent
and Enterprise System Partners, and the 2017 acquisition of
LabAnswer.
Accenture invested nearly $1.5 billion globally on 34
acquisitions in its 2020 fiscal year to acquire critical skills and
capabilities in strategic, high-growth areas of the market.
The acquisition requires prior consultation with the relevant
works councils and would be subject to customary closing
conditions. Financial terms of the transaction are not being
disclosed.
About Accenture
Accenture is a global professional services company with leading
capabilities in digital, cloud and security. Combining unmatched
experience and specialized skills across more than 40 industries,
we offer Strategy and Consulting, Interactive, Technology and
Operations services—all powered by the world’s largest network of
Advanced Technology and Intelligent Operations centers. Our 506,000
people deliver on the promise of technology and human ingenuity
every day, serving clients in more than 120 countries. We embrace
the power of change to create value and shared success for our
clients, people, shareholders, partners and communities. Visit us
at www.accenture.com.
Forward-Looking Statements
Except for the historical information and discussions contained
herein, statements in this news release may constitute
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as “may,”
“will,” “should,” “likely,” “anticipates,” “expects,” “intends,”
“plans,” “projects,” “believes,” “estimates,” “positioned,”
“outlook” and similar expressions are used to identify these
forward-looking statements. These statements involve a number of
risks, uncertainties and other factors that could cause actual
results to differ materially from those expressed or implied. For a
discussion of risks and actions taken in response to the
coronavirus (COVID-19) pandemic, see “Our results of operations
have been significantly adversely affected and could in the future
be materially adversely impacted by the COVID-19 pandemic” under
Item 1A, “Risk Factors” in Accenture plc’s Quarterly Report on Form
10-Q for the quarterly period ended May 31, 2020. Many of the
following risks, uncertainties and other factors identified below
are, and will be, amplified by the COVID-19 pandemic. These risks
include, without limitation, risks that: Accenture and OpusLine
will not be able to close the transaction in the time period
anticipated, or at all, which is dependent on the parties’ ability
to satisfy certain closing conditions; the transaction might not
achieve the anticipated benefits for Accenture; Accenture’s results
of operations have been significantly adversely affected and could
in the future be materially adversely impacted by the COVID-19
pandemic; Accenture’s results of operations could be adversely
affected by volatile, negative or uncertain economic and political
conditions and the effects of these conditions on the company’s
clients’ businesses and levels of business activity; Accenture’s
business depends on generating and maintaining ongoing, profitable
client demand for the company’s services and solutions including
through the adaptation and expansion of its services and solutions
in response to ongoing changes in technology and offerings, and a
significant reduction in such demand or an inability to respond to
the evolving technological environment could materially affect the
company’s results of operations; if Accenture is unable to keep its
supply of skills and resources in balance with client demand around
the world and attract and retain professionals with strong
leadership skills, the company’s business, the utilization rate of
the company’s professionals and the company’s results of operations
may be materially adversely affected; Accenture could face legal,
reputational and financial risks if the company fails to protect
client and/or company data from security breaches or cyberattacks;
the markets in which Accenture operates are highly competitive, and
Accenture might not be able to compete effectively; changes in
Accenture’s level of taxes, as well as audits, investigations and
tax proceedings, or changes in tax laws or in their interpretation
or enforcement, could have a material adverse effect on the
company’s effective tax rate, results of operations, cash flows and
financial condition; Accenture’s profitability could materially
suffer if the company is unable to obtain favorable pricing for its
services and solutions, if the company is unable to remain
competitive, if its cost-management strategies are unsuccessful or
if it experiences delivery inefficiencies; Accenture’s results of
operations could be materially adversely affected by fluctuations
in foreign currency exchange rates; as a result of Accenture’s
geographically diverse operations and its growth strategy to
continue to expand in its key markets around the world, the company
is more susceptible to certain risks; Accenture’s business could be
materially adversely affected if the company incurs legal
liability; Accenture’s work with government clients exposes the
company to additional risks inherent in the government contracting
environment; if Accenture is unable to manage the organizational
challenges associated with its size, the company might be unable to
achieve its business objectives; Accenture’s ability to attract and
retain business and employees may depend on its reputation in the
marketplace; if Accenture does not successfully manage and develop
its relationships with key alliance partners or fails to anticipate
and establish new alliances in new technologies, the company’s
results of operations could be adversely affected; Accenture might
not be successful at acquiring, investing in or integrating
businesses, entering into joint ventures or divesting businesses;
if Accenture is unable to protect or enforce its intellectual
property rights or if Accenture’s services or solutions infringe
upon the intellectual property rights of others or the company
loses its ability to utilize the intellectual property of others,
its business could be adversely affected; Accenture’s results of
operations and share price could be adversely affected if it is
unable to maintain effective internal controls; changes to
accounting standards or in the estimates and assumptions Accenture
makes in connection with the preparation of its consolidated
financial statements could adversely affect its financial results;
many of Accenture’s contracts include fees subject to the
attainment of targets or specific service levels, which could
increase the variability of the company’s revenues and impact its
margins; Accenture might be unable to access additional capital on
favorable terms or at all and if the company raises equity capital,
it may dilute its shareholders’ ownership interest in the company;
Accenture may be subject to criticism and negative publicity
related to its incorporation in Ireland; as well as the risks,
uncertainties and other factors discussed under the “Risk Factors”
heading in Accenture plc’s most recent Annual Report on Form 10-K,
Quarterly Report on Form 10-Q and other documents filed with or
furnished to the Securities and Exchange Commission. Statements in
this news release speak only as of the date they were made, and
Accenture undertakes no duty to update any forward-looking
statements made in this news release or to conform such statements
to actual results or changes in Accenture’s expectations.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201027005133/en/
Velislava Le Fevre Accenture +33 1 53 23 46 18
velislava.lefevre@accenture.com
Accenture (NYSE:ACN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Accenture (NYSE:ACN)
Historical Stock Chart
From Mar 2023 to Mar 2024